Pharmacologic ATF6 activation has substantial potential for ameliorating tissue-specific defects in ER proteostasis implicated in diverse diseases including systemic amyloid diseases, ischemic heart disease, diabetes, and neurodegenerative disorders (Hetz et al., 2015; Plate and Wiseman, 2017). This evidence concerns the gene ATF6 and diabetes mellitus.